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INTRODUCTION 
 
 Humans have been plagued by diseases throughout the history of 
civilization. Medical science has conquered many of the infectious diseases that 
formerly destroyed large populations. But cancer is still considered as the worse 
disease of non-epidemic kind. It is notorious in the sense that it can affect anyone 
without any regard to race or religion, rich or poor, from young to old alike.  
 
 
In humans and other mammals, the breasts form a secondary sexual 
feature of females and are the source of nutrition for the neonate, although they 
are also present in rudimentary form in males. It is both ironic and tragic that 
malignant neoplasms arising from this organ, readily accessible to self-
examination and clinical diagnosis, continue to be a heavy toll among women.  
The incidence of female breast cancer is rising rapidly between the ages of 35 and 
50. Invasive ductal carcinoma comprises the largest group of malignancy ie.65% 
- 80% of breast carcinoma73.  
 
Carcinoma breast can be proved by pathological examination of breast 
tissue only. Fine Needle Aspiration biopsy is a safe procedure that is 
diagnostically superior to trucut needle biopsy50.  An accuracy rate of 96.5% was 
obtained28. AgNOR study done in histologic specimen showed high AgNOR count 
in malignant lesions than benign lesions41. 
 
  
“EARLIER THE DIAGNOSIS, BETTER THE PROGNOSIS” 
 
 
 Having this in mind, the present study has been conducted to assess the 
accuracy of fine needle aspiration biopsy, trucut biopsy and to evaluate and 
compare AgNOR score in breast neoplasms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIM OF THE STUDY 
 
 
1. To statistically evaluate the occurrence of breast lesions in and around 
Madurai. 
 
2. To find out the Clinicopathological correlation wherever possible.  
 
3. To assess the diagnostic accuracy of the various procedures adapted for 
pathological evaluation of breast lesions. 
 
4. To evaluate and compare the AgNOR score in benign and malignant 
neoplasms of breast.   
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
EMBRYOLOGY  
 The breast is a highly modified sudoriferous gland that develops as 
ingrowths from the ectoderm to form the alveoli and ducts. Supporting 
vascularised connective tissue is derived solely from mesenchyme. Each 
mammary gland develops as ingrowths of ectoderm and initiates a primary bud 
of tissue in underlying mesenchyme. Each primary bud initiates the development 
of 15 to 20 secondary buds or outgrowths. In the fetus, epithelial cords develop 
from the secondary buds and extend of into the surrounding connective tissues of 
the chest wall. Lumina develop in the out growths to from lactiferous ducts with 
prominent branches77.  
 
ANATOMY AND DEVELOPMENT  
 Located within the superficial fascia of the anterior thoracic wall, the 
breast is composed of 15 to 20 lobes of glandular tissue of the tubuloalveolar type. 
Fibrous connective tissues connect the lobes; adipose tissue is abundantly 
interposed between the lobules. The mature breast of the female extends from the 
level of the second or third rib to the inframammary fold at approximately the 
sixth or seventh rib. Transversely, it extends from the lateral border of the 
sternum to the anterior axillary or mid axillary line77.  
 
 HISTOLOGY 
 The mammary gland consists of 15 to 20 lobes, each of which is an 
individual compound tubulo-alveolar type of gland. The lobule contains groups 
of small tubules that are lined with cuboidal or low columnar epithelium. These 
tubules resemble the ducts. More defined tubules are also seen such as a small 
intralobular duct or a large intralobular excretory duct that emerges from the 
lobule to join the interlobular duct. The lobules are surrounded by a loose, fine 
connective tissue the intralobular connective tissue, which contains fibroblasts, 
lymphocytes, plasma cells and eosinophils77.  
 
BREAST – TUMOR AND TUMOR LIKE CONDITIONS 
 The Edwin smith surgical papyrus (3000-25000 B.C) was the first 
document that referred to carcinoma of the breast. The author of the papyrus 
concluded that there was no treatment for cancer of the breast.  
  
In the second century A.D., Galen inscribed one of the classic clinical 
observations, as “The breast tumour exactly resembles the animal crab. In this 
disease, the veins extending out from the unnatural growth take the shape of a 
crab’s legs82.  
 
FIBROADENOMA  
 
Deschenes14 found a prevalence of 8.3/1000 in a population of Canadian 
women aged 40-59 in the first round of mammographic screening.  
Hughes90 and colleagues have defined four clinical subgroups of fibroadenoma 
based upon the size of the lump:  
 
1. Small palpable superficial lesion, which measures less than 5mm in 
diameter and may remain, unchanged for many years.  
 
2. The most common type, making up approx 80% of clinical cases, which 
grow to 1-3cm in diameter before becoming static.  
 
3. Juvenile or Giant fibroadenoma which is rare, undergo very rapid growth 
to    15-20 cm. 
 
4. An uncommon lesion, 10%, measuring 4-5cm, found at any age in 
perimenarchal and perimenopausal age group. 
 
Apocrine metaplasia is found in a significant minority of cases with recorded 
frequency of between 11 and 35%. Scleorsing adenosis has been reported in <10% 
of fibroadenoma. Squamous metaplasia occurs only rarely.  
 
Extensive areas of myxoid change were found in the rare syndrome 
(Carney syndrome) described by Carney and Toorkey9 in which myxomas might 
also be present in other organs. In Juvenile fibroadenoma, the epithelial 
proliferation is often florid and even atypical.  
 
 
FIBROCYSTIC CHANGE 
Fibrocystic change affects women between 20 and 50 yrs of age but the 
majority occurring between 40 and 50 yrs. 
Page and Dupont64 have noted that flattened cysts are larger than 
apocrine cysts suggesting that cysts lined by flattened epithelium represent the 
late stage of development in which the active secretory element is no longer 
present. 
 
 Wellings and Alpers99 stated that no apocrine metaplasia was seen in the 
13 to 19 year age group whereas this change was identified is over half of those 
above 30yrs.  
 
CYSTOSARCOMA PHYLLODES  
 Muller90 coined the name phyllodes meaning leaf like appearance. 
Incidence ranges from 0.3 to 1% of primary breast tumors as reported by Dyer et 
al90. Norris and Taylor61 who assessed the behaviour of 94 cases in relation to 
tumour size, nature of tumour margin, degree of cellular atypia and mitotic 
counts. Pietruska and Barnes69 based on the assessment of 42 cases defined 
benign tumors as those with predominantly pushing margins, no or minimal 
stromal cell atypia and 0-4 mitosis per 10 HPF. Malignant tumour had 
predominantly infiltrating margins, moderate to marked stromal atypia and 10 
or more mitosis/10HPF. They also recognised a borderline group with pushing or 
infiltrative margins, moderate stromal atypia and 5-9 mitoses per 10 HPF.  
 
 Mofatt et al59 studied 32 cases of phyllodes where, benign, borderline and 
malignant being 22, 5 and 5 cases respectively. They studied one case of 
recurrence in borderline and malignant phyllodes.  
 
 Symmer90 in his study in Nottingham found that 68% of the tumours were 
benign, 16% borderline and 16% were malignant.  
 
DUCTAL CARCINOMA IN SITU   
 DCIS was first recognized by Bloodgood6 (1983). Lewis and Geschickter46 
described comedo DCIS, although they failed to distinguish invasive from insitu 
carcinoma.  
 
 Azzopardi3 highlighted lobular ‘cancerization’ in DCIS. Page63 described 
cribriform, micro papillary and other non-comedo DCIS. All these studies stated 
that the perimenopausal women were commonly affected.   
 
High nuclear grade in DCIS is closely correlated with large cell size, larger 
tumour size, and increased grades of intraductal necrosis, increased c-erb/b-2 
protein expression, high cellular proliferation, p53 protein expression and absence 
of ER and PR expression. They show increased incidence to develop invasive 
carcinoma90.  
 
 
 
LOBULAR CARCINOMA IN SITU (LCIS)  
 Foote and Stewart25 (1941) described the histological features and assigned 
the term lobular carcinoma in situ. LCIS requires (1) Involvement of acini by 
characteristic cells (2) cells, fill, distend and distort the acini. Incidence is greater 
before menopause (only <10% postmenopausal).  
  
 Page65 (1991) stated that 2/3 of LCIS would advance to invasive carcinoma 
within the first 15 years after biopsy. However, Rosen74 (1978) recorded that 
invasive carcinoma developed even after 15 years, with the median follow up of 5 
yrs.  
 
INVASIVE DUCTAL CARCINOMA  
 Rosen74 (1979) accounts that 75% of cancer death in breast cancer is due to 
invasive ductal carcinoma. According to current opinion ductal as well as lobular 
invasive carcinoma starts in the Terminal duct lobular unit (TDLU).  
 
 Azzopardi3 stressed, the work of Wellings and colleagues on the point of 
view of the site of origin of most ductal carcinoma is TDLU. The incidence is 
common in perimenopausal persons.  
 
INFILTRATING LOBULAR CARCINOMA 
 Tavassoli91 (1992) was the first to account that the invasive carcinoma of 
the breast composed of small cells with a linear growth pattern.  
 
 In 19th century Comil and Waldeyer90 traced them as intra lobular 
carcinoma. Foote and Stewart25 (1946) introduced the term LCIS and infiltrating 
lobular carcinoma from a study of 300 cases.  
 
TUBULAR CARCINOMA  
 Fisher23 (1977) first found an uncommon variant where the tumour cells 
form microtubules and some of them were arranged in cords.  
 Martinez and Azzopardi51 (1987) recognized a similar variant within 
infiltrating ductal carcinoma. Tavassoli91 (1992) did not accept a tumour forming 
tubules as a variant of ILC. She regarded them as a tumour displaying both 
ductal and lobular patterns of invasion.  
 
 Mc Divit53 and colleagues (1982) have pointed out the morphological 
features of tubular carcinoma. This carcinoma is in fact a readily recognizable 
subtype composed as it is of distinct tubular structures with open lumina lined by 
a single layer of epithelial cells. They lack myoepithelial investment. It usually 
presents with ductal carcinoma in majority of cases.  
 
MUCINOUS CARCINOMA 
 It is also referred as gelatinous, mucoid and colloid carcinoma and 
characterized by abundant extracellular mucin surrounding nests of carcinoma 
cells. Such carcinomas are typically circumscribed. This neoplastic growth 
pattern is associated with a relatively favourable prognosis, provided that the 
carcinoma consists almost entirely of mucinous growth pattern73.  
 
MEDULLARY CARCINOMA  
 Foote60 (1949) defined it as a specific type of invasive breast cancer 
apparently having a favourable prognosis. It is characterized by a circumscribed 
growth pattern, pronounced nuclear pleomorphism and mitotic activity, a 
syncytial arrangement of the neoplastic cells and a lymphocyte or plasma cellular 
infiltrate.  
PAPILLARY CARCINOMA  
 In the past the term papillary carcinoma has been used in a broad sense 
and should be distinguished from invasive and in situ types.  
 
 Fisher22 (1980) pointed out that it is important in terms of prognosis and 
management to distinguish the two types. They are frequent in elderly and less 
than 2% are only symptomatic.  
 
 Siranukgul and Tavassoli83 (1993) identified 9 cases of invasive micro 
papillary carcinoma and concluded that they were different from that of Ductal 
NST carcinoma.  
 
 However, Luna, More47 and colleagues who found 27 cases which showed 
micro papillary differentiation out of 986 cases of invasive carcinoma and they 
considered this tumour types to be aggressive.  
 
ADENOID CYSTIC CARCINOMA 
 Azzopardi3 (1979) accepted an incidence of 1% of these tumours. 
Lamovec44 (1989) who found 6 examples of adenoid cystic carcinoma in a total of 
5994 cases of breast cancer.  
 At least 50% of adenoid cystic carcinoma arises in sub and periareolar 
region. This is the only form of invasive carcinoma, which typically demonstrates 
myoepithelial participation. There is no lymph node metastasis. The prognosis is 
very good.  
 
 Lamovec44 (1989) observed neither recurrence nor metastasis in his cases. 
Peters and Wolff67 (1992) stated that no patients died of disease but two 
developed local recurrence after five years of surgery.  
 
CARCINOMA WITH METAPLASIA 
 The term metaplastic carcinoma covers a heterogenous range of uncommon 
entities and has been used loosely by many authors to refer to a variety of breast 
malignancies of mixed epithelial and mesenchymal appearances. Metaplastic 
carcinoma is currently believed to arise from either myoepithelial or epithelial 
cells90.  
 
 Ease. V et al20 (1989) by an immunocytochemical study of 14 cases proved 
sarcomatoid carcinoma of the breast.  
 
 Wargotz ES, Nortis HU98 (1989) said that metaplastic carcinoma of breast 
were matrix producing carcinoma meaning that carcinomas with a direct 
transition from the epithelial to a chondroid or osteoid stromal component without 
interspersed spindled or giant cell areas.  
APOCRINE CARCINOMA  
 Frable and Kay26 (1968) found that apocrine carcinoma constitute 1% of 
mammary carcinoma. Azzopardi3 (1979) accounted a lower incidence of 0.3% 
only. He accepted those tumours, which has PAS positive granules as apocrine 
tumours.   
 
 Mossler52 (1980) found that apocrine carcinomas constituted 4% of their 
prospective series. Histological definition by Eusebi et al19 (1986) has pointed out 
that patterns of apocrine cell differentiation can be seen in practically any type of 
carcinoma of breast, including papillary and medullary types. Apocrine 
carcinoma comprises of two intermingled cell types. One (type A) has abundant 
granular eosinophilic cytoplasm (granules are PAS +ve after diastase digestion). 
The second (type B) displays abundant cytoplasm in which fine empty vacuoles 
are seen.  
 
 
SECRETORY JUNVENILE CARCINOMA  
 Mc Divitt and Stewart54 (1966) first reported this carcinoma in children 
and were later seen in 87-year-old patient also. Norris and Taylor62 (1970) found 
135 tumours in women less than 30yrs old.  
 
 Three patterns are present in varying combinations – Honey combed, 
compact and tubular. Tubules are mostly present in the central fibrotic areas, 
which are angulated and lined by cuboidal to flat cells. Honeycomb pattern is 
composed of follicular and micro cystic structures, which give a spongy 
appearance. The neoplastic cells have a large amount of pale staining cytoplasm90. 
 This carcinoma has an extremely favourable prognosis in children and 
adolescents. Sullivan et al89 reported first case of recurrent secretory carcinoma. 
In adults it is more aggressive. Meis56 (1993) reported axillary lymph node 
metastasis in adults.  
 
FINE NEEDLE ASPIRATION BIOPSY OF THE BREAST 
 
For the last 160 years exfoliated and abraded samples of cells have been 
collected from accessible anatomical surface especially from areas like bronchus 
and cervix50.  
 
Mean while, Heyden and Menetriers57 (1883) employed needles to obtain 
cells and tissue fragments to isolate pneumonic microorgansims and diagnose 
pulmonary carcinoma respectively.  
 
It was in Europe and particularly Scandinavian country that FNAC as the 
technique flourished in 1950 and 196050. 
 
For example, in one study by Russ75 (1978) about one in eight breast 
cancers diagnosed with FNA biopsy were initially considered benign on physical 
examination.  
 
It has been emphasized by Fisher22 that FNA biopsy should be performed 
before surgery to identify lesions requiring excision with margins. Since excision 
biopsy may destroy the margin of tumour.  
 
FNA biopsy in addition can significantly reduce the number of 
unnecessary surgeries for benign disease, which can result in scarring and 
disfigurement of the breast 15, 66.  
According to Howell36 (1993) possible contraindications to its use include 
multicentric cancers, a tumour larger than 4cm, suspicious, widespread, 
mammographic calcifications, centrally located tumour, large, pendulous breasts 
and pregnant or elderly patients.  
  
Grant31 (1986) studied the following statistics regarding FNA biopsy from 
summary of 18 reported cases.  
 Sensitivity    -  92.5% 
 Specificity    -  99.8% 
 Positive predictive value  -  99.7% 
 Negative predictive value  -  94.2% 
 Accuracy    - 96.5% 
 
FNA biopsy is an excellent, cost effective diagnostic modality. The use of 
FNA biopsy may reduce the cost of diagnosis by as much as 90% compared with 
hospitalization and excisional biopsy, as indicated in studies by Kaninsky40 
(1984). 
 
Johnson TL, Kini SR39 (1989) studied that irregular nuclear shape, 
irregular chromatin distribution, loss of cell cohesion, necrosis and the absence of 
benign epithelial cells and bipolar nuclei are all features in apocrine carcinoma. 
 
E. Wilkinson et al18 (1989) analysed 276 aspirates and found out some 
tumours are less likely to be diagnosed like lobular carcinoma, tubular 
carcinoma, small cell ductal carcinoma and as well as minimal and in situ 
cancers. 
Layfield et al45 (1989) pointed out that various forms of degeneration like 
cystic, haemorrhagic, necrosis and fibrosis can also result in the paucity of 
diagnostic cells. 
 
Greely, Frost32 (1997) studied that some ductal carcinomas have equally 
small relatively uniform neoplastic cells; conversely, lobular carcinoma may have 
larger cell similar to those of ductal carcinoma NOS. 
 
Sethis et al80 (1997) pointed out that cells with intracytoplasmic lumina, 
when present as single or dispersed cells, are a significant observation. They are 
generally associated with malignancy, particularly lobular carcinoma in situ and 
atypical lobular hyperplasia. 
  
Stanley et al88 (1993) pointed out that smears showing abundant hyaline 
globules, nuclear enlargements and hyperchromasia allow a confident diagnosis 
of adenoid cystic carcinoma. 
 
Dabbs et al13 (1994) studied that cells of some lobular carcinoma have the 
appearance of signet ring cells and the pleomorphic variant show features more 
like poorly differentiated ductal carcinomas. 
 
Jeffrey and Ljung38 (1994) pointed out that it is difficult to distinguish 
intracystic or intraductal papillary carcinoma from intraductal papilloma or 
florid papillomatosis as it is not possible to predict if a well differentiated 
papillary carcinoma is invasive or non invasive. 
Venegas et al96 (1994) studied cytologically that high nuclear grade lesions 
are biologically more aggressive and necrosis appears to impart a worse 
prognosis in low to intermediate nuclear grade lesions. 
 
Dutta et al17 (2001) studied 51 cases of breast lumps by fine needle 
aspiration cytology of which 28 were malignant and benign lesions were mastitis, 
fibroadenoma and fibrocystic disease. Diagnostic accuracy of FNAC was 90.2%. 
 
Ribeiro – Silva et al70 (2001) by fine needle aspiration found out 3 cases of 
metaplastic carcinoma of breast which is often confused with benign and other 
malignant entities. 
 
Chaiwum et al11 (2002) studied 2375 cases of breast lesions by FNA from 
1994 to 1999, 48% were benign, suspicious for malignancy were 5%, malignant 
were 15%, unsatisfactory 32%, Showing sensitivity of 84.4% and Specificity of 
99.5%. 
 
Gomez et al30  (2002) studied total of 30 cases of breast tumour with 
papillary pattern which are characterized by an abundance of cellular material, 
three dimensional papillary clusters without fibrovascular connective tissue 
cores, small papillae arranged in cell walls, tall columnar cells and isolated naked 
nuclei. 
Sneige86 (2000) studied the cytomorphologic features of in situ 
proliferative breast lesions and found a spectrum ranging from those of a simple 
benign lesion to atypical to those indistinguishable from invasive carcinoma. 
Bojia et al7 (2001) studied 120 patients by FNAC and found out 16 patients 
to have carcinoma and 86 cases were found to have fibroadenoma of the breast. 
The Sensitivity was 94.3% and Specificity was 78.6%. The high sensitivity and 
specificity results obtained ascertain that FNAC is the most reliable diagnostic 
method.  
 
Ustun et al95 (2002) studied cytological features of FNAC of the breast 
from 21 patients with proven LCIS which were described and compared with 
surgical specimens. Aspirates from 8/21 cases had cell groups diagnostic for or 
compatible with LCIS. Two cases turned out to be invasive lobular carcinoma. 
Other 11 aspirates were benign. 
  
Mansoor, Jamal49 (2002) studied the efficacy of breast FNA in 72 cases 
that were having both FNA cytology and follow up histology diagnosis. The 
Sensitivity was 98.4% and Specificity was 60%. 
 
Ariga et al1 (2002) compared the diagnostic accuracy of fine needle 
aspiration of clinically suspicious palpable breast masses in women younger and 
older then 40 years of age. A total of 1158 FNA’s performed between 1982 and 
2002 in women with palpable breast masses. The Sensitivity was 98% and 
Specificity was 99% overall. 
 
Young et al102 (2002) pointed out that breast carcinomas were correctly 
identified as malignant and the values of exact diagnosis were 65% for ductal 
carcinoma, 20% for lobular adenocarcinoma, 12% for medullary carcinoma and 
27% for mucinous variety. This study shows that FNAC of the breast is the 
reliable method for the diagnosis of breast carcinoma. 
 
Hardisson et al34 (2003) by FNA reported four cases of solid papillary 
carcinoma of the breast. Mean age was 66 years. Cytology demonstrated 
moderately to highly cellular smears with irregular groups of predominantly 
monolayered epithelium composed of small, polygonal or cuboidal cells with 
eosinophilic cytoplasm and rounded eccentrically placed nuclei. 
 
AGNOR TECHNIQUE IN HISTOPATHOLOGY OF BREAST CARCINOMA  
 
Cell kinetics plays an important role in tumour behaviour. Proliferation 
rates of the tumour can be assessed to determine the behaviour of a particular 
tumour. The cell cycle can be divided into four phases based on the nuclear 
chromatin activity. They are S, G1, G2 and Go phases. There is a short resting 
phase of the cell undergoing replication at the ‘S’ phase. G2 is the second resting 
phase before active mitosis. Thus, the DNA content at the end of ‘S’ phase in an 
indicator of proliferative activity AgNOR detects the DNA content at this stage92.  
 
During the phase of active DNA replication, strips of DNA containing 
RNA genes are seen inside the nucleolus. These DNA fragments are actively 
transcribing with the help of polymerase I enzyme. They are considered as 
ribosomal factories, cell cycle in controlled by a few enzymes called M phase 
promoting factors92.  
 
This factor has two subunit proteins 
1) 34 kd protein, which is the product of the CDC2 gene.  
2) 45 kd subunit consisting of proteins, which accumulate during cell cycle 
and are destroyed by the end of mitosis.  
 
These proteins are named as ‘cyclins’. The inactivation of these cyclins 
inactivates M phase promoting factors also and so, this protein is required to end 
mitosis in a cell cycle.  
Nucleolar organizer regions (NOR) are loops of DNA that transcribe 
ribosomal RNA. They are located in the acrocentric chromosomes 13, 14, 15 and 
21. At ultra – structural level, NORs are termed fibrillary centers and can be 
demonstrated by means of in situ hybridization to localize ribosomal genes. 
NORs are associated with certain proteins. There NOR Associated proteins 
(NORAPs) are Polymerase I C23 (nucleolin) and B23. These proteins are thought 
to play a role in RNA transcription93.  
 
NORs were first visualized in 1975 by means of a simple silver staining 
technique that recognizes these argyrophilia-associated proteins. AgNORs appear 
as black dots in the nucleus. The AgNOR content is expressed as mean AgNOR 
count for 50-100cells. After DNA synthesis, in the G2 phase of the cell cycle a 
diploid nucleus might contain 20 AgNORs. In practices the AgNORs are so 
closely packed that it is difficult to distinguish one AgNOR from another. The 
argyrophilia of the NOR associated protein (NORAPs) acts as a marker of 
ribosomal DNA and possibly reflects its transcriptional phase. The number of 
visible AgNORs therefore indicates the current phase of transcription92. 
 
Interest has been focused on seeking reliable guide to patient’s prognosis 
by measuring the cell proliferation and correlating these data with the tumour’s 
potential for metastases and recurrence because the behaviour of a tumour is 
generally thought to reflect its growth rate. One of the methods of measuring the 
proliferation rate is the AgNOR technique, which determines Nucleolar 
Organiser regions (NOR) associated proteins. The nuclei of malignant cells 
contain NOR of a significantly different number and size from those in normal, 
reactive or benign neoplastic cells92. 
 
The NORs attracted lot of attention because of the claims that their 
frequency within the nuclei is significantly higher in malignant cells than in 
normal, reactive or benign neoplastic cells. Their potential value in diagnostic 
histopathology was because they can be easily demonstrated in routinely 
processed tissue sections. 
 
A quantifiable apparent increase in the mean AgNOR count of a cell 
population in tissue sections resulted if: 
1. Cell proliferation was so active that nucleolar dissociation was present 
in many cells, when the AgNOR were seen throughout the nucleus. 
2. There was a defect of the nuclear association, which resulted in 
AgNOR dispersion. 
3. Cell ploidy increased, resulting in a real increase of AgNOR bearing 
chromosome. 
4. Transcriptional activity increased resulting in the prominence of 
otherwise inconspicuous AgNORs. 
 
Benign cells show only 1-2 AgNOR per nucleus, which was attributed to 
the difficulty in perceiving the individual AgNORs, when they aggregated within 
a relatively small nucleus. In malignancy, or with increased cell proliferation, 
AgNORs get dispersed throughout the nucleus to a varying extent, enabling the 
histologist to count them more readily. Therefore, the quantification of AgNORs 
depends on the degree of dispersion or disaggregation of the relatively large 
number of AgNORs in the nucleus. One great advantage of this technique is that, 
previously stained cytology slides can be reused for silver staining, thus providing 
an excellent guide to the diagnosis especially in doubtful cases and when extra-
unstained slides are not available. 
 
The major disadvantages are: 
1. The counting procedures adopted are usually manual and hence 
long and tedious. 
2.  Observer error is the major cause of inaccuracy and inconsistency. 
3. The dots of AgNOR interphase nuclei need not always correspond 
actively to the number of such types in the karyotype93.  
4. Overlap and coalescence may result in misjudged counts92. 
 
Ultra – Structural appearance of Mammalian Nucleoli  
a. Granular component composed of distinct spherical shaped 
granular each out 15nm in diameter. 
b. Dense fibrillar component consisting of lightly packed 
electron dense 3-5nm thick fibrils. 
c. Fibrillar center – consisting of a loose network of fibrils with 
a little greater average diameter 4-8nm than the dense 
fibrillar component.  
 
Canepa et al8 (1993) studied nucleolar organizing region as a prognostic 
factor in infiltrating ductal carcinoma of breast. They analysed 170 cases of 
infiltrating ductal carcinoma over a period of 138 months and found out that 
those cases with average score below 9.5 showed favourable prognosis and above 
9.5 had unfavourable outcome.  
 
Roller et al71 (1993) studied nucleolar organizer regions in human breast 
cancer. They examined the number of AgNOR’S in 56 cases of malignant breast 
lesions and 20 being cases using routinely fixed material. They could find out a 
clear-cut difference between benign breast diseases as compared with breast 
carcinoma by high AgNOR counts.  
Yoshida et al101 (1994) studied a clinicopathological evaluation of NOR 
proteins in human breast cancer. They pointed out that AgNOR count was low in 
small sized tumours i.e., less than 2 cms, than large ones, i.e., more than 2 cms. 
The group with recurrence had a higher count i.e., >9. AgNOR is useful in 
evaluating cell proliferative activity and helps to predict postoperative 
recurrence.  
 
Basu et al5 (1995) studied a total of 72 cases, which were ductal 
carcinomas. The AgNOR scores showed a tendency to increase with higher 
grades of malignancy. Their mean AgNOR count was (16.63 ± 7.09).  
 
Simha et al82 (1996) studied the prognostic value of argyrophilic nucleolar 
organiser regions (AgNORs) in breast lesion. AgNOR counts correlated with 
tumour size, mitosis and desmoplasia. ER/PR negative tumours showed a 
tendency for high NOR counts.  
 
Kumar et al43 (1997) evaluated in 46 patients that the AgNOR count was 
significantly higher in breast carcinoma (6.61 ± 1.75) and found better 
correlation with the increase in the size of the tumour, stage of the cancer, 
number of lymph nodes and tumour recurrence.  
 
Mehrota A, Chandra T55, (1998) determined the significance of AgNOR 
counts in FNAC smears and corresponding paraffin section by using an one step 
colloidal staining method. AgNOR counts were significantly higher in FNAC 
smears in malignant neoplasms in comparison to paraffin sections in the same 
groups of cases.  
Sinha SK et al84 (1998) evaluated the cytomorphological features (nuclear 
grade and smear pattern) and AgNOR counts in 60 cases of carcinoma breast. 
AgNOR staining and C-erb B-2 immunostaining were also done in each case. 
Significantly 23 postmenopausal cases with carcinoma breast, the tumour cells 
were positive for c-erb b-2 and an association was found between the nuclear 
grade and high AgNOR counts.  
 
Ceccarellic et al10 (2000) found that AgNOR protein was a proliferation 
related parameter that could be used as a prognostic indicator in breast tumour 
pathology. They also found that there was significant association between 
AgNOR protein quality and tumour prognosis.  
 
Hasnan and Jayaram35 (1996) adopted the argyrophil technique for 
staining NORs in FNA cytological smears of 56 breast lesions comprising 31 
benign and 26 malignant cases. From their study, they concluded that AgNOR 
score of 5 and less strongly favours benign lesions whereas a score of above 5 
could be in favour of a malignant lesion.  
 
Kruger et al42 (2000) investigated to what extent analysis of silver stained 
nucleolar organizer regions is cell cycle dependent in breast cancer and to assess 
the prognostic value of an AgNOR analysis that takes into consideration the cell 
cycle status of tumour cells. In comparison to the noncycling tumour cells, cycling 
ones exhibited significantly higher AgNOR numbers (mean values 3.84 ± 1.09 vs 
2.40 ± 0.78 per nucleus).  
 
Khanna et al41 (2001) studied 73 patients (46 malignant and 27 benign) 
with breast lumps. In all cases FNAC samples and histologic specimen were 
studied by conventional and silver staining for AgNOR. AgNOR count was 6.94 ± 
2.74 in FNAC and 6.57 ± 2.73 in histology of malignant tumours.  
 
MATERIAL AND METHODS 
 
Of the 2, 11, 201 patients treated in Govt. Rajaji Hospital, Madurai from        
July 2003 to August 2005 there were 816 cases of breast tumours. Of these 407 
were benign and 409 were malignant. The present study evaluates various 
parameters including incidence of the breast tumours and their diagnostic 
accuracy by means of FNAC and Trucut biopsy. AgNOR score is calculated for 
benign and malignant tumours. The following types of breast biopsy materials 
were received from our hospital.  
 
1. FNAC 
2. Trucut biopsy 
3. Lumpectomy 
4. Mastectomy  
5. Re-excisional Biopsy. 
 
While the FNAC smears were received fixed either in 95% ethyl alcohol, 
rectified spirit or isopropyl alcohol, the rest of the biopsy materials were received 
fixed in 10% buffered formalin. Trucut specimens were subjected to 
histopathological examination in toto. Lumpectomy specimens received were 
examined for their size and dimension. Regarding mastectomy specimens, the 
macroscopic examination included overall size of the specimen, dimensions and 
appearance of skin with measurements of scars or incisions, appearance of nipple 
and areola, presence of muscle and axillary tissue and location of any distinct 
palpable lesion. The specimens were cut into thin slices (about 5mm) and then 
examined by careful visual inspection and palpation. With breast carcinomas, the 
size, contour and consistency of the tumour were noted. Also, its location, 
including the distance from the nearest surgical margin was noted.  
 
 Samples for histologic examination were taken from the tumour 
(especially around its periphery to appreciate in-situ changes and invasion), 
nipple, skin quadrant (to assess intramammary spread of tumour and 
multicentricity). The axillary fat was dissected for lymph nodes and all the nodes 
were subjected to study. The tissue slices were processed in various grades of 
alcohol and xylol. Paraffin blocks were subsequently prepared and thin sections 
cut to obtain optimum results. All the biopsy materials were stained routinely 
with Hematoxylin and Eosin4.  
 
AGNOR STUDY IN BREAST NEOPLASMS 
 Tissue sections of benign and malignant tumours were analysed and 55 
samples were selected for AgNOR study and comparison. These include both 
biopsies and mastectomy specimen.  
 
METHODS  
 The formalin fixed, routinely processed and paraffin embedded tissue 
blocks were collected. 
 
 AgNOR staining4 was done using the one step silver – colloid technique.  
PREPARATION OF STAINING SOLUTION 
 Solution A: 2% gelatin in 1% formic acid  
 Solution B: 50% aqueous silver nitrate solution 
 
WORKING SOLUTION 
 One part of solution A mixed with two parts of solution B. 
 
STAINING METHODS  
 Sections were cut at 3-5 mm thickness from the blocks. They were 
dewaxed in xylene and they hydrated to double distilled deionised water.  
 The sections were exposed to freshly prepared working solution for 60 
minutes in the dark at room temperature.  
The silver colloid was then washed off with deionised water.  
The sections were dehydrated through alcohol, cleared in xylene and 
mounted using DPX mounting medium.  
 
COUNTING PROCEDURE92 
 Nucleolar organizer regions in silver staining are observed as black dots 
within the nucleus, which may remain discrete or in aggregates. Rest of the 
nucleus stains pale yellow.  
 
 The standardized approach proposed was followed in counting AgNOR. 
100 nuclei were assessed in each slide and mean number of dots per nucleus was 
determined by light microscope using an oil immersion (100x) objective. 
 There are two approaches to count AgNORs. 
 Firstly, all silver stained structures could be counted, but when lying in 
groups each cluster (almost aggregated or partly disaggregated nucleoli) treated 
as one structure [Type 1 method]. 
 Secondly, where AgNORs can be separately seen within a nucleolus, each 
AgNOR could be counted as a unit, together with the smaller AgNORs seen 
outside the Nucleolus (Type 2 method). Both methods have been followed in our 
study. 
 
    Mean NOR count in tumour nuclei  
AgNOR INDEX = 
Mean NOR count in the nuclei of Non neoplastic 
breast tissue  
 
 A total of 100 nuclei is randomly chosen from both tumour part and Non-
neoplastic breast tissue in each sections, were evaluated and NOR index 
calculated. 
 Statistical method used for comparison studies of AgNOR scores is 
mention below. 
TEST OF SIGNIFICANCE27 
      x1 – x2 
 Z  =  
                      S √ 1   +  1 
                            n1       n2 
FINE NEEDLE ASPIRATION CYTOLOGY 
 The cytological materials were obtained in the form of smears, which were 
fixed in 95% alcohol for PAP and H & E staining. The aspiration syringes used 
were 10-25ml and the needle size between 22-23 gauges. Standard methods of 
staining were employed4.  
 Appropriately labeled specimens were subjected for microscopic 
examination. The slides from all the specimens were studied and placed into one 
of the following categories viz. Benign, malignant, tumor like lesions, and 
inflammatory lesions.   Table 1 shows Peterse’s criteria of benign and malignant 
breast cytology. Amongst these, the breast tumours were analysed with FNAC 
and trucut biopsies for benign and malignant nature and the significance of these 
diagnostic procedure were evaluated. The sensitivity, specificity and accuracy of 
these diagnostic procedures were calculated by using the formula shown in Table 
2.  
 
Photographs of specimens and photomicrographs of slides are represented 
at relevant areas in discussion. The classification of mammary neoplasms used in 
this study is based one the one adopted by the WHO97.  
 
 
 
 
 OBSERVATION AND RESULT 
 
INCIDENCE OF BREAST TUMOURS 
 In the two-year study period from August 2003 to July 2005, 32, 421 
specimens were received from the Govt. Rajaji Hospital, Madurai. Of these, 
breast tumour accounted for 816 cases. Hence, the overall incidence of breast 
tumours as per the attendance of cases is 2.51%.  
 
 The number of benign and malignant breast tumours was 407 and 409 
respectively. Thus, the incidence of benign tumours of the breast 49.8% and the 
incidence of malignant breast tumours 50.1%.  
 
Diagram 1, shows the year wise distribution of breast tumours during the 
study period. In the academic year 2003 – 2004 benign cases were 217 and 
malignant were 189. In the year 2004 – 05 benign cases were 190 cases and 
malignant cases were 220.  
 
AGE INCIDENCE  
 The distribution of breast tumours according to age is shown in Diagram 
2 while the benign breast tumours had a peak incidence 46.6% in the third 
decade, the peak incidence (38%) of malignant breast tumour is seen in the fifth 
decade.  
 
SEX INCIDENCE  
 Of the total 816-breast tumour, 813 cases occurred in female (incidence of 
99.6%) whereas only 3 cases (4%) occurred in males as shown in Table 3. It is 
clear from the illustration that all the cases seen in male were malignant breast 
tumour.  
 
BENIGN TUMOUR AND TUMOUR LIKE LESION OF THE BREAST  
 46.8% of the breast tumours encountered in the study were benign. Table 
4 lists the various types of benign breast tumours and their incidence with regard 
to the total number of breast tumours. It is obvious that fibroadenoma is the 
most common breast tumour and comprised 30.14% of the benign breast 
tumours (Fig 1, 2).  
 
MALIGNANT TUMOUR OF THE BREAST  
 Of the 32,421-biopsy material analysed in the two-year study, there were 
409 cases of malignant breast tumour with an overall incidence of 1.26%. During 
the two years period the overall incidence of breast tumour is 2.51%. The 
incidence of benign tumours of the breast is 49.8% and the incidence of 
malignant tumours is 50.1%.  
 
 Table 5 depicts the decennial incidence of malignant breast tumours 
compared to the total number of malignant tumour that was encountered in each 
decade in this Institution.  
 
SIGNS AND SYMPTOMS  
 The incidence of various signs and symptoms is shown in Table 6. 90.5% 
of the cases sought treatment with complaints of lump in the breast, which in 
many cases was painless. 12 patients (2.9%) noted a bloody nipple discharge 9 
cases (2.2%) reported with ulceration. 18 cases (4.4%) reported with painful 
lump.  
 
CLINICAL STAGING OF CARCINOMA OF BREAST  
 The clinical staging system jointly adopted by the International union 
against – cancer (UICC) and American joint commission on cancer staging (AJC) 
is followed in the study and depicted in Annexure IV. Table 7 shows the 
percentage of patients in each stage. In the current study 47 cases were in stage I, 
70 cases were in stage II, 62 cases were in stage IIIA, 15 cases were in stage IIIB, 
5 cases were in stage IV and 73 cases were unstaged.  
 
HISTOLOGIC DISTRIBUTION OF MALIGNANT TUMOUR  
 Table 8, shows the incidence of the various histological types of malignant 
breast lesions. In the current study, 2 cases were ductal carcinoma in situ (Fig 3, 
4), 389 cases were invasive ductal carcinoma (NOS), 4 cases were invasive lobular 
carcinoma (Fig 7, 8), one case was invasive ductal carcinoma with predominant 
intraductal carcinoma (Fig 5, 6), 1 case was medullary carcinoma 10 cases (Fig 9, 
10) were colloid carcinoma (Fig 11, 12) and 2 cases were Paget’s disease of nipple          
(Fig 13, 14).  
CYTODIAGNOSIS  
 Pre-operatively FNAC was performed on 607 patients of these only 532 
yielded cellular aspirates of which 260 were positive for benign lesions (48.8%)   
(Fig 15, 16, 17), 272 were positive for malignancy (51.1%) (Fig 18, 19, 20, 21), 73 
were cases negative for malignancy, 1 was false negative (0.18%) and 1 was false 
positive (0.18%).  
 
TRUCUT BIOPSIES 
 Trucut biopsies were performed on 280 cases, which were suspected for 
malignancy of which 256 had the required yield. All the 256 cases were positive 
for malignancy (100%) (Fig 23, 24). The sensitivity & specificity obtained for this 
diagnostic procedure was 95.8% and 100% respectively. The Accuracy of the test 
was 96%. 
 
AgNOR SCORE  
Of the total 816 cases in this study, 35 cases were selected as shown                  
in Table 9. All the selected sections stained by AgNOR staining technique were 
carefully examined under light microscope with oil immersion objective. The 
nuclei were stained light yellow and the nucleolar organizer regions were seen as 
black coloured dots within the nuclei (Fig 25, 26, 27). The numbers of black dots 
were counted in 100 nuclei in each section and the mean AgNOR value for each 
case was determined as shown in Table 10.  
 
LYMPHNODE METASTASIS  
 Out of total 409 cases, axillary node involvement was found clinically in 
262 cases (64%) of these 212 cases (81%) were proven positive histologically                  
(Fig 22, 28) and one node showed granulomatous reaction (Fig 29). Of the 
remainder, sinus histiocytosis was found in 27 cases (10.3%), 23 cases (9%) were 
found to be reactive nodes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  DISCUSSION 
 
 Sidney J.Cutler81 who analysed data from the Connecticut tumour 
registry and California tumour registry revealed that there has been an increase 
in the number of diagnosed cases of breast cancer per lakh women younger than 
55 year of age. This was more than balanced by improvement in patient survival, 
resulting in a decrease in mortality from breast cancer.  
 
 During the early 1980s mammographic screening was introduced, and the 
number of women of appropriate age undergoing screening increased steadily to 
current reported rates of 60% to 80%. In 1994, after a lag of time of about 10 
years, the mortality rate started to decline90.  
 
 Glauco Frizzera29, advisor American cancer society comments that the 
incidence of breast cancer over the past 50 years showed 3 distinct phases.  
 
1. Between 1940 & 1982 – steady annual rate of increase of 1% per year. 
2. Between 1982 & 1987 – incidence was 4% per year.  
3. Between 1990 + 1994 – The incidence appear to statistic at approximately 
110.2 cases / 10,000 women. 
 
SEER79 cancer statistics review 1973 – 1999 shows the breast cancer 
incidence from 1994 to 2000 as 379 cases / 1,00,000 women. 
 
 
 The current study also shows an increase incidence in this beginning of the 
millennium compared to the past 3 decades. Technically, the increased incidence 
has been ascribed to the increased use of mammography. Moreover, the rise in 
prevalence of breast cancer risk factors may also be responsible for the apparent 
increase. 
 
CLINICOPATHOLOGICAL CORRELATION 
Benign Breast Neoplasm 
 
 Fibroadenoma and fibrocystic disease of breast present mostly as a 
palpable mass. Fibroadenoma is the one of the commonest causes of a lump in the 
female breast accounts to about 10 cases / 1000 women90. The current study has 
an incidence of 30.14%.  
 
Malik R and Bharadwaj48 studied the lumps in breast of males and 
females. Of the lumps in females 89% were benign and of these 49% were 
reported fibrocystic diseases of breast. Jamal AA et al37 quoted that the incidence 
of benign breast disease was 85.3%. In the current study, the incidence of benign 
breast disease was 49.8%. 
 
FIBROCYSTIC CHANGE 
Fibrocystic change affects women between 20 and 50 yrs of age but the 
majority occurring between 40 and 50 yrs. 
 
Page and Dupont64 have noted that flattened cysts are larger than 
apocrine cysts suggesting that cysts lined by flattened epithelium represent the 
late stage of development in which the active secretory element is no longer 
present. 
 
 Wellings and Alpers99 stated that apocrine metaplasia was not found in 
the 13 to 19 year age group whereas this change was identified in over half of 
those above 30yrs.  
 
CYSTOSARCOMA PHYLLODES  
 Microscopically the two key features of phyllodes tumour are stromal 
hypercellularity and presence of benign glandular element as an integral 
component of the neoplasm73.  
 
 Pietruszka et al69 have subdivided these tumours into benign borderline 
and malignant groups based on histologic features. An important diagnostic 
criterion for malignant overgrowth of the glands by the sarcomatous stroma, so 
that, low power views of the tumour show only stroma without epithelial 
elements. Presence of tumour necrosis and heterolgous stromal elements signifies 
an adverse prognosis90. In the current study, the incidence of malignant phyllodes 
was 0.24%. 
 
 Metastasis, which is restricted only to malignant lesion, shows stromal 
elements only. However, recurrances can occur with both types and simulate 
original tumour multiple recurrence of a borderline neoplasm can get 
differentiated and produce metastasis.  
 Muller90 coined the name phyllodes meaning leaf like appearance. 
Incidence ranges from 0.3 to 1% of primary breast tumors as reported by Dyer90 
et al. Norris and Taylor61 who assessed the behaviour of 94 cases in relation to 
tumour size, nature of tumour margin, degree of cellular atypia and mitotic 
counts. Pietruska and Barnes69 based on the assessment of 42 cases defined 
benign tumors as those with predominantly pushing margins, no or minimal 
stromal cell atypia and 0-4 mitosis per 10 HPF. Malignant tumour had 
predominantly infiltrating margins, moderate to marked stromal atypia and 10 
or more mitosis/10HPF. They also recognised a borderline group with pushing or 
infiltrative margins, moderate stromal atypia and 5-9 mitoses per 10 HPF. The 
current study 13 cases of Cystosarcoma phyllodes (1.5%). Of which 1 case was 
malignant. 
 
 Mofatt et al59 studied 32 case of phyllodes where, benign, borderline and 
malignant being 22, 5 and 5 cases respectively. They studied one case of 
recurrence in borderline and malignant phyllodes. Symmer90 in his study in 
Nottingham found that 68% of the tumours were benign, 16% borderline and 
16% were malignant.  
 
MALGINANT BREAST NEOPLASMS 
Non-invasive carcinoma 
 In the late 1960’s Gallagher and Martin published the results of their 
whole organ section studies and affirmed the transition that established a 
stepwise evolution of invasive breast cancer from benign epithelium through in-
situ and subsequent invasive stages90.  
This recognition allowed them to coin the term ‘Minimal Breast cancer’ in 
which was included DCIS, LCIS and minimally invasive cancers smaller than 5 
cm. These with proper therapy would translate into a 10-year cure probability of 
90% or more90. Fisher et al22 quoted a high incidence of DCIS tumours i.e., 5%. 
The current study which has an incidence of 5% is lower than the other study 
performed in India Viz. Usha94 et al. Table 11 source the percentage of patients in 
each stage, and illustrates the result of two studies conducted by BCDDP (Breast 
cancer detection demonstration project) and SEER79 (surveillance, Epidemiology 
and End Results-conducted by USA’s National Cancer Institute). In all these 
studies the number of malignant cases with FNAC proof has been taken into 
account. The result of the BCDDP study fairly correlated with present study, 
whereas the SEER project reports higher incidence of patients in stage II (57%) 
compared to 37% in the present study. This can be explained by the fact that 
breast cancer specific screening programs are a common place in the USA 
whereas it is not economically feasible in developing countries like India. As a 
consequence more number of patients, present in higher stages. That the Indian 
women are more socially inhibited also contributed to the delay in diagnosis. It is 
therefore clear that the increased awareness and mass-screening program for 
breast cancer in our country has aided detection of many pre-invasive malignant 
tumours. A comparative analysis of incidence encountered by Fisher et al22 and 
Usha et al94 is also furnished (Table 12). While it was satisfying to note that in 
most cases all the three studies represented a similarity in range of incidence, 
Fisher et al22 study depicts a higher incidence of the non-invasive cancer. The 
screening programs in the west has helped to detect many cancers in their pre-
invasive stage thereby accounting for the apparent increase in non-invasive 
cancers and the corresponding decrease of invasive cancers. The most common 
histological type in accordance with the results of other studies was invasive 
ductal carcinoma (N.O.S.).  
 
 Based on Scott et al’s recent classification of DCIS one case was found in 
intermediate grade with cribriform pattern and focal necrosis and the other case 
was low grade with low nuclear grade and absence of necrosis. When the 
carcinoma is confined to the ductal system without violation of the basement 
membrane, axillary lymph node involvement is unlikely90. 
 
Invasive carcinomas  
 Tumour in this category are all those in which stromal invasion in 
detectable, whether an in situ component is identifiable or not and regardless of 
the relative proportion of these two components. The classification of invasive 
breast carcinoma in corporate a wide range of criteria such as cell type, type and 
amount of secretion, architectural feature and pattern of spread90.  
 
Invasive ductal carcinoma – Not otherwise specified (IDC – NOS). 
 This comprises the largest group of malignant mammary tumour. 
Consisting 65% - 80% of breast cancer73. In the current study it comprises about 
95.1%. WHO defines this entity by exclusion as the most frequently encountered 
malignant lesion of the breast, not falling into any of the other categories of 
invasive mammary carcinoma. These are also designated generically as the 
classic or ordinary type. They are seen throughout the age range of breast 
carcinoma and most common in mid to late fifties73. 
 
 Grossly, most tumours were of the comedo type and had an irregular 
stellate (Crab-like) outline with yellowish grey, hard, gritty cut surface often 
exhibiting yellow flecks of elastin. Areas of necrosis, hemorrhage and cystic 
degeneration were often seen. A minority of tumours had grossly circumscribed 
margins that are presumed to have a better prognosis. Histologically, the 
neoplastic cells were seen either in diffuse sheets, well-defined nests, and cords or 
as individual cells. There was a variable amount of glandular or tubular 
differentiation. Some showed necrosis within the ducts and micro calcifications. 
Some tumours showed growth patterns varying from solid sheets devoid of 
stroma to those with abundant, densely fibrotic to cellular stroma, the so called 
‘scirrhous type’. Foci of squamous metaplasia and clear cell changes were seen. A 
lymphoplasmocytic infiltration was present at the interphase between tumour 
and stroma in many cases. Many tumours showed invasion of perineural spaces, 
lymph vessel and blood vessel, which represent unfavourable prognostic findings. 
Several studies show nipple invasion in 23% to 31% of IDC (NOS) cases90. In the 
current study 120 cases of IDC (NOS) showed invasion of the nipple (29.3%) and 
in a large majority the tumour was located in a zone less than 2.5 cm from the 
nipple. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INVASIVE DUCTAL CARCINOMA WITH PREDOMINANT  
INTRADUCTAL COMPONENT 
 Azzopardi et al2 who propounded this concept that was incorporated in 
the recent WHO classification, describe this as, the carcinoma which were 
overwhelmingly intraductal and contain only small foci of stromal invasion. It 
was suggested that only those tumours in which the intraductal carcinoma was at 
least 4 times greater than the invasive component, should be included. The 
current study encountered one such tumour with an incidence of 0.2%.  
 
INVASIVE LOBULAR CARCINOMA (ILC)  
 Foote and Stewart25 established the term ILC in 1941 with the publication 
of the classic paper on this carcinoma. The reported incidence of has varied from 
1% - 14%51. The current study quotes to0.9% and the median age at diagnosis 
was between 45 and 56 years, which is in accordance with other studies where it 
was 52 years. Grossly, a classic ILC forms a firm to hard tumour with irregular 
borders. Another gross manifestation is formation of innumerable fine, hard 
nodules. A desmoplastic stromal reaction, linear arrangement of carcinoma cells 
“Indian – File pattern” and their tendency to grow in a circumferential fashion 
around ducts and lobules (targetoid growth) were the peculiar diagnostic features 
of classic ILC, emphasised by Foote and Stewart25. The tumour cells are small 
and medium sized, uniform in staining properties and exhibit relatively little 
irregularity. Clues for diagnosis on FNAC include a sparsely cellular sample, 
small cells with scanty cytoplasm dispersed singly or linear / Indian file arrays.  
 
MEDULLARY CARCINOMA  
 Medullary carcinoma constitutes 7% of breast tumour in several studies 
with a mean age ranging from 46 to 54 years. The current studies show 
compatible data with an incidence of 0.24% and mean age of 48 years. Grossly, 
these tumours have well-circumscribed margin firm in consistency with a 
lobulated or nodular cut surface. The extent of necrosis if present is directly 
related to tumour size. Foote and Stewart25 described a constellation of definitive 
histopathologic features, which include  
1. Lymphoplasmacytic reaction: This must involve at least 75% of the 
periphery and be present diffusely in the substance of the tumour  
2. Microscopic circumscription: Edge of the tumour should have a smooth, 
rounded contour that appears to push side rather than infiltrate the 
breast  
3. Syncytial growth pattern of most of the tumour growth (>75%)  
4. Poorly differentiated nuclear grade  
5. High mitotic rate. 
 
These tumours have an overall lower frequency of axillary node 
involvement and have a good prognosis even in stage II. When the tumour 
resembles medullary carcinoma with >75% syncytial growth pattern, but lacks 
all of the necessary features, which has been designated as ‘Atypical’ medullary 
carcinoma.  
 
 
MUCINOUS CARCINOMA  
This type, also known as colloid mucinous or gelatinous carcinoma, is 
characterised by large amount of extracellular epithelial mucin, recognisable 
microscopically, surrounding and within tumour cells73.  
 
Pure mucinous carcinomas contain at least 50% of the tumour growing in 
a mucinous pattern and with extracellular mucin constituting at least 33% of the 
lesion. This criterion helps to differentiate from focal mucinous differentiation 
found in other carcinomas in which the prognosis depends on the latter73. Pure 
forms have a very low incidence of local metastasis and a better prognosis. 
Grossly these tumours exhibit a circumscribed margin often accentuated by red 
to purple zone of congested parenchyma and a gelatinous cut surface. Synder et 
al87 found an overall incidence of pure forms as 2% with a greater mean age at 
diagnosis then mixed forms. The current study parallels with an incidence of 
2.4% an mean age of 53 years.  
 
INFILTRATING DUCTAL CARCINOMA WITH PAPILLARY PATTERN  
WHO defines this as a rare carcinoma in which invasive pattern is 
predominantly in the form of papillary structures. The same architecture is 
usually displayed in the metastasis. Frequently foci of intraductal papillary 
growth are recognizable24.  In the present study 4 cases have been reported with 
an incidence of 1% and a mean age of 53 years.  
 
PAGET’S DISEASE OF NIPPLE 
Sir James Paget described this disease more than a century ago90. The 
incidence in Fisher’s22 study and in the current study in 2.3% and .48%. 
Clinically it presents as a weeping eczema – like lesion centered in the nipple and 
later involving the areola. Microscopically, Paget’s cells, which are large, clear 
cells with typical nuclei are seen within the epidermis, usually concentrated along 
the basal layer. These cells may occur singly or in clusters and typically contain 
mucin or rarely melanin granules73. An associated carcinoma is seen in more 
than 95% of these cases, which have virtually all been intraductal carcinoma 
with an invasive component73. The current study reveals only 2 cases (0.48%) of 
which one had an invasive ductal component.  
 
MALE BREAST CANCER  
 Breast Carcinoma is an uncommon neoplastic condition among men, 
accounting for not more than 1% of all breast cancers73 (0.1% in this study). The 
mean age at diagnosis is 60 yrs (55 years in the current study). The gross features 
are similar to carcinoma of female breast. Approx 85% of male breast cancer are 
of the invasive ductal carcinoma (N.O.S) type (100%), one showing carcinoid 
pattern and other two showed moderately or poorly differentiated carcinoma73. 
Unfavourable Prognostic factors regardless of nodal status are tumour size 
greater than 2cm and poor histologic differentiation90. 
 
 
FNAC AND TRUCUT BIOPSIES STUDY  
 Romanidis72 quoted that FNAC done for breast cancer had sensitivity 
99% and specificity (96%) in their study. Franzen and Zajicek50 who have a very 
long experience at the Karolinska Institute reported that 80% of carcinomas 
were definitely diagnosed 10% equivocal and another 10% missed in other 
words, false negatives.  
 
 Most studies reveal an average sensitivity of 87% and specificity of 100%. 
In the current study the sensitivity rate of FNAC was 99.6% & specificity of 
98.6% for both benign and malignant cases as shown in Table 13. The accuracy 
for benign cases was 99.4% & for malignant cases was 95.1%.  
  
In the current study total number of cases analysed for FNAC was 607. 
260 cases were reported as benign disease of the breast. False positivity was 
reported for one case and false negativity for one case. Sensitivity rate obtained 
was 99.6% and specificity rate as 98.6%. The accuracy of FNAC in benign breast 
neoplasm accounts to 99.4%. In the current study, the trucut biopsy analysed 
subsequently for 502 cases of which 221 cases where diagnosed as benign 
neoplasm, 256 cases diagnosed as carcinoma one case was false negative and one 
case was false positive. Sensitivity was 95.2% specificity was 99.3% accuracy was 
95.1%. As many tumours on which a trucut was performed were greater than 
2.5cm in diameter, it accounted for the high index of sensitively. The overall 
sensitivity rates in various series have ranged from 75% to 90%.  
 
 Ariga et al1 quoted a 99% sensitivity, and 99% specificity in their study of 
FNAC in palpable breast masses. The accuracy of FNAC was 99%  
 
 Bojia et al7 in his study reported that the sensitivity of the FNAC and 
excision biopsy of breast lesion was 94.3% and specificity as 78.6%, accuracy 
rate as 84.3%.  
 
 Mansoor et al49 reported in their study the sensitivity, specificity and 
accuracy as 98.4%, 60%, 93% respectively. Zhong et al103 quoted 97.3% as 
sensitivity, 97.7% as specificity and 97.4% as accuracy in their study of 951 cases 
of FNAC smear study.  
 
Grant31 concluded with the following statistics regarding FNAC quoting 
sensitivity (92.5%) specifying 99.8% accuracy – 96.5%. Dutta et al17 studied that 
the diagnostic accuracy of FNAC was 90.2% in their study. Chaiwun et al11 
reported in their study that FNAC had provided a sensitivity of (84.4%) & 
specificity (99.5%) Yong et al100 in their study obtained an accuracy of 90% for 
FNAC and 67% accuracy for Trucut biopsy in surprises breast lumps.  
 
 Scopa et al78 quoted in their study the sensitivity, specificity and accuracy 
of FNAC as 90%, 100% 94% respectively. For Trucut biopsies the sensitivity 
rate was 89%, specificity as 100%, and accuracy as 90%.  
 
 In Comparison with the above-mentioned studies and the current study, 
the sensitivity specificity and accuracy of the FNAC, Trucut and excisional 
biopsy quoted in the current study are higher than that of other studies. In the 
current study the sensitivity index of FNAC was 99.6%, which in higher than the 
sensitivity index of trucut biopsy in 95.2%. The diagnostic accuracy of FNAC was 
99.4% which in higher than the accuracy of Trucut (95.1%).  
 
 This ascertains that the FNAC has a better diagnostic accuracy then the 
trucut biopsies. The reason behind FNAC being more accurate is as follows.  
 
1. Adequacy of smeared material 
2. FNAC done from a more representative area, as the needle is poked in 
different directions thus providing sampling from different foci. 
3. Good Fixation and staining preparation of the smears. 
4. Efficient reporting system.  
False positive diagnoses were avoided, as the interpretive errors were 
negligible in the hands of experienced cytopathologists. Carcinomas that have the 
highest potential for false negative diagnosis include those showing extensive 
fibrosis or extracellular matrix with decreased number of malignant cells. By 
having these in mind, false negative diagnosis was avoided.  
 
 
 
 
AGNOR SCORE IN BENIGN AND MALIGNANT BREAST TUMOURS 
 Roller et al71 in their study found out that malignant breast lesions had an 
increased AgNOR score than the benign breast diseases. Basu et al5 found a mean 
AgNOR score of 16.63 ±7.09 in their study on malignant cases. 
 
Hasnan, Jayram35 concluded that AgNOR score of 5 or less strongly 
favours benign lesions whereas a score above 5 could be in favour of a malignant 
lesion. 
 
The current study showed no significant difference in AgNOR score 
between ductal epithelial cells of fibroadenomas and fibrocystic disease. There 
was significant difference in AgNOR score between DCIS and infiltrating ductal 
carcinoma. It was observed that the AgNOR score progressively increased with 
infiltrating ductal carcinoma. It has been observed that Type 2 method of 
counting have higher AgNOR scores than Type 1 method of counting. The 
average of the AgNOR index of all benign cases was3 and Malignant was 9. 
 
 
 
 
In the current study, Type 1 counting method showed less value of 
AgNOR score then the Type 2 method. So the values obtained by Type 2 method 
have been considered in this discussion. The AgNOR score of 17 cases of benign 
breast diseases is 3.2 ± 1.2. The AgNOR index was 3.  
Mean AgNOR counts in tumour nuclei 
AgNOR index =  
Mean AgNOR counts in the nuclei of Non-neoplastic 
breast tissue 
  
 
The AgNOR score for malignant tumours was 7.9 ± 3.1. Ductal in situ 
stage of the breast cancer showed AgNOR score of 61 ± 1.3. The infiltrating 
ductal and Lobular carcinoma showed AgNOR score of 9 ± 2.1. The AgNOR 
index was 6 for DCIS and 9 for invasive carcinomas. It has been observed that 
AgNOR scores are directly proportional to grading i.e., with increased grades the 
AgNOR scores also increased and can be used for assessing the clinical outcome 
and prognosis of the cases. However the AgNOR scores in our study shows a 
significant high value for malignant than benign.  
 
 AgNOR scores revealed that the benign lesions had a value below 3 and 
the malignant lesions had a score of 7 and above. Statistical significance showed a 
calculated value of Z (Test of significance-1.781). The average AgNOR score of 
malignant lesions are certainly higher then those of the benign lesions.  
 
Recalling the work done by Hasnan, Jayaram35 (1996) it has been found 
that Crockers type 2 counting method is more useful in grading the tumours than 
type 1 method. This observation of Jayaram35 has made out in our study where 
high-grade tumours have high AgNOR score when compared to low-grade 
tumours. 
 
 
 
 
 SUMMARY AND CONCLUSION 
 
The study indicates that the overall incidence of breast neoplasms is 
2.51%. 
 
 The incidence of benign and malignant tumours was more or less equal 
i.e., 49.8% and 50.2% respectively. Benign and malignant breast tumours were 
most commonly encountered in females. With male patients, malignant breast 
lesion was commonly encountered.  
 
 In females the peak incidence of benign and malignant tumours where at 
the third and fifth decade respectively. In males the incidence of malignant 
tumours was in the fifth decade. The complaint for which most patients (96%) 
sought treatment was a lump in the breast that was painless in most instances. 
 
 Among the benign lesions, Fibroadenoma comprised the maximum 
proportion of cases accounting for 60.4%. In the malignant lesions infiltrating 
ductal carcinoma (Nos) comprised the maximum accounting for 86%. The non-
invasive carcinomas accounted for only 0.5%. Illiteracy and Poverty play a hand-
in-glove role in the delay in diagnosis of Pre-invasive breast cancers in Indian 
women. 
 
 Preoperative FNAC and Trucut biopsies have a sensitivity index of 99.6% 
and 95.8%. The accuracy of these diagnostic tools was 99.6% and 96% for FNAC 
and Trucut respectively. The accuracy rate of FNA biopsy increases when the 
cytopathologist performs the FNA biopsy and uses immediate assessment to 
guide specimen adequacy. This procedure has several advantages. 
 
1. Provide rapid, accurate diagnosis. 
2. Serve a cost-effective role in the treatment of breast manes. 
3. Differentiate cysts from solid tumour and serve as a therapeutic 
procedure. 
4. Provide psychological relief of anxiety for patients with benign breast 
lesions. 
 
Trucut biopsies and excision biopsy are painful and cosmetically 
disabling. If done in experienced hands, it avoids false negatives and provides 
complete histological diagnosis that helps in further management plans. But due 
to inadequate material and biopsies taken from less representative area, it led to 
false negative diagnosis. So the accuracy rate of this diagnostic tool is far below 
that of FNAC in the current study. 
 
AGNOR STUDY 
 AgNOR scores revealed that the benign lesions had a value below 3 and 
the malignant lesions had a score of 7 and above. AgNOR study concludes that 
the statistical comparison of AgNOR scores is significantly higher malignant 
lesions than in benign breast lesions.  
 
ANNEXURE I 
PROFORMA 
 
Serial No :     Name :  
Biopsy No. :     Age :  
Cyt. No. :     Sex : 
Unit   :      
Clinical diagnosis  
Breast  : Right/Left / Both 
Specimen : Excisional (Lumpectomy / mastectomy) 
   Incisional (Trucut / FNAC) 
Macroscopic Examination  
Specimen size  : 
Skin and Nipple : 
Tumor Size   : 
Colour   : 
Tumor margins  : Circumscribed / Infiltrative  
Posterior margin  :  
Lymphnode  : 
Number 
Size  
C/S 
Histological type of lesion:   Fibroadenoma  
        Others    
DCIS 
Invasive ductal carcinoma (Nos) 
Invasive lobular carcinoma  
Invasive ductal carcinoma with 
predominant intraductal carcinoma 
Medullary carcinoma  
Mucinous carcinoma  
Paget’s disease of nipple  
Others  
Skin            Free / Involved  
Nipple      Free / Involved  
Muscle      Free / Involved 
Lymphnodes     
 Total number   :  
 No. of nodes involved  : 
 Other Findings  : 
F.N.A.C. Findings    :  
 Cellularity  
 Tumour cells  
 Myoepithelial cells  
 Inflammatory cells 
 Others   
  Fat cells / Fibrocytes / RBCs 
AgNOR study  
 AgNOR score  
 
Pathological Staging: 
I    / II A / II B /    III  A / III  B   / IV 
 
 
  
ANNEXURE II 
 
W.H.O. CLASSIFICATION OF BREAST TUMORS 
 
I EPITHELIAL TUMORS  
A. Benign 
1. Intraductal Papilloma 
2. Adenoma of the nipple  
3. Adenoma  
 (a) Tubular  
 (b) Lactating  
4. Others:  
B. Malignant 
1. Non-Invasive:  
(a) Ductal carcinoma – in – situ (DCIS)  
(B) Lobular carcinoma sin-situ (LCIS) 
2. Invasive  
(a) Invasive ductal carcinoma (NOS) 
(b) Invasive ductal carcinoma with a predominant intraductal component  
(c) Invasive lobular carcinoma  
(d) Mucinous carcinoma 
(e) Medullary carcinoma  
(f) Papillary carcinoma  
(g) Tubular carcinoma  
(h) Adenoid cystic carcinoma  
(i) Secretory (Juvenile) carcinoma 
(j) Apocrine carcinoma 
(k) Carcinoma with Metaplasia 
1. Squamous type  
2. Spindle cell type  
3. Cartilagenous and osseous type  
4. Mixed type  
(l) Others  
3. Paget’s disease of the nipple  
II MIXED CONECTIVE TISSUE AND EPITHELIAL TUMORS  
(a) Fibroadenoma  
(b) Cystosarcoma phyllodes (Benign / Borderline / Malignant) 
(c) Carcinosarcoma  
III MISCELLANEOUS TUMORS  
(a) Soft tissue tumors  
(b) Skin tumors 
(c) Tumors of hematopoietic and lymphoid tissues.  
 
 IV UNCLASSIFIED TUMORS  
V MAMMARY DYSPLASIA / FIBROCYSTIC DISEASE  
a) Duct ectasia  
b) Inflammatory pseudotumors  
c) Hamartoma  
d) Gynecomastia  
e) Others 
 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE III 
 
Definition 
Sensitivity  -  The number of Carcinomas diagnosed and expressed as a  
percentage of the total number of carcinomas aspirated. 
   a 
Sensitivity =   × 100 
  a+c 
 
 
Specificity - The number of correctly identified benign lesions and  
   expressed as a percentage of the total number of benign  
   lesions aspirated. 
 
    d 
Specificity =   × 100 
  b+d 
 
        a + d  
Accuracy 
  a + b + c + d 
 
TEST OF SIGNIFICANCE86  
      x1 – x2 
 Z  =  
                      S √ 1   + 1 
                            n1     n2 
      
 
 ANNEXURE IV  
TNM CLASSIFICATION OF BREAST CANCER 
 
Primary Tumor (T)  
 Tx  -  Primary Tumor cannot be assessed.  
 To  -  No evidence of primary tumor 
 TIS  -  DCIS / LCIS OR Paget’s disease of nipple with no tumor  
 T1  -  Tumor ≤ 2 cm in greatest dimension  
 T1a  -  ≤ 0.5 cm in greatest dimension  
 T1b  -  > 0.5 - ≤ 1 cm in greatest dimension 
 T1c  -  Tumor > 1 cm - ≤ 2 cm in greatest dimension  
 T2  -  Tumor > 2 cm and ≤ 5 cm in greatest dimension  
 T3  - Tumor > 5 cm  
 T4  -  Tumor any size with direct extension to chest wall or skin  
Regional Lymph Nodes (N)  
Nx  - Regional Lymph nodes cannot be assessed eg: Not removed  
  for study 
 No  - No regional LN metastasis  
 N1  - Metastasis to movable ipsilateral axillary node (s) 
 N2  - Metastasis to ipsilateral axillary node (s) fixed to one  
   another or to other structures.  
 N3  - Metastasis to ipsilateral internal mammary Lymph node (s)  
Distant Metastasis  
 Mx  - Distant metastasis cannot be assessed.  
 Mo  - No distant metastasis  
 M1  - Distant metastasis 
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                Fig 1 Microscopic appearance of Fibroadenoma intracanalicular type 
                 (H&E, x100)  Path No.1661/05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 Microscopic appearance of Ductal Carcinoma with cribriform 
pattern. (H&E, x400) Path No- 505/05 
Fig 2 Benign Cystosarcoma phyllodes - Gross specimen showing leaf like 
areas with haemorrhage. Path. No.889/05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4 Microscopic appearance of Fibrocystic disease showing few ducts 
with in situ ductal carcinoma and some ducts showing apocrine changes 
with cystic macrophages. Inset-apocrine change. (H&E, x100) 
Path No-861/04 
Fig 5 Microscopic appearance of Lymphatic invasion by Carcinomatous 
cells. Inset shows low power view of involved Lymph vessel.  
(H&E, x400)Path No.801/04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7 Infiltrating Lobular Carcinoma – Gross showing Grayish white tumour 
mass and nodules with infiltrating margins. Path. No.5224/04 
Fig 6 Microscopic appearance of Invasive Ductal Carcinoma showing 
Predominant Intraductal Papillary Component. Inset shows magnified view   
of the Papillae. (H&E, x400) Path No- 648/03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8 Microscopic appearance of Infiltrating Lobular Carcinoma showing 
“Indian File Pattern”. Inset showing the same. (H&E, x400) Path No-5224/04 
Fig 9 Medullary Carcinoma - Gross showing well circumscribed 
tumour mass. Path. No.1105/05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10 Microscopic appearance of Medullary Carcinoma showing 
poorly differentiated tumour cells with pushing margins. Inset shows 
the magnified view of Lymphoplasmacytic reaction.  
(H&E, x100) Path No:1105/05 
Fig 11 Mucinous Carcinoma - Gross showing tumour tissue 
exhibiting a circumscribed margin and a gelatinous cut surface. 
Path. No.1332/05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12 Microscopic appearance of Mucinous Carcinoma showing 
tumour cells in lakes of mucin. Inset shows the magnified view of 
tumour cells.  (H&E, x100) Path No: 1332/05 
Fig 13 Microscopic appearance of Papillary Carcinoma showing 
Papillary Structures with Fibrovascular core. Inset shows magnified 
view of a Papillae. (H&E, x100) Path No: 648/04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14 Microscopic appearance of Shows Pagets Disease of Nipple 
with Intraepidermal location of Pagets cells. Inset shows the 
magnified view of Pagets Cells. (H&E, x400) Path No: 621/05 
Fig 17 Fibroadenoma - Smear showing tight clusters of uniform ductal 
epithelial cell in a haemorrhagic background. (H&E, x100) Cyt No: 947/04    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18 Infiltrating Ductal Carcinoma - Smear showing groups of malignant 
epithelial cells in a haemorrhagic background. Inset shows magnified view of 
the same. (H&E, x100) Cyt No. 1541/04   
Fig 21 Mucinous Carcinoma - Smear showing aggregates of malignant 
epithelial cells in a mucinous background. Inset shows magnified 
tumour cells. (H&E, x100) Cyt No. 101/04  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 22 Lymphnode Metastasis - Smear showing Clumps of Malignant 
epithelial cells admixed lymphocytes and Plasma cells. (PAP, x400)  
Cyt No:  1511/04 
Fig 28 Lymphnode Metastasis - Gross showing subcapsular deposit of 
Infiltrating Ductal Carcinoma. Path No.20/05 
20 / 05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 29 Microscopic appearance of lymphnode with granulomatous reaction to 
the tumour cells.   (H&E, x100) Path No. 1873/04 
Fig 17 Fibroadenoma - Smear showing tight clusters of uniform ductal 
epithelial cell in a haemorrhagic background. (H&E, x100) Cyt No: 947/04    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18 Infiltrating Ductal Carcinoma - Smear showing groups of malignant 
epithelial cells in a haemorrhagic background. Inset shows magnified view of 
the same. (H&E, x100) Cyt No. 1541/04   
Fig 21 Mucinous Carcinoma - Smear showing aggregates of malignant 
epithelial cells in a mucinous background. Inset shows magnified 
tumour cells. (H&E, x100) Cyt No. 101/04  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 22 Lymphnode Metastasis - Smear showing Clumps of Malignant 
epithelial cells admixed lymphocytes and Plasma cells. (PAP, x400)  
Cyt No:  1511/04 
Fig 28 Lymphnode Metastasis - Gross showing subcapsular deposit of 
Infiltrating Ductal Carcinoma. Path No.20/05 
20 / 05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 29 Microscopic appearance of lymphnode with granulomatous reaction to 
the tumour cells.   (H&E, x100) Path No. 1873/04 
Fig 25 Photograph showing the pattern of AgNOR staining in 
fibroadenoma. Path No.1662/05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 26 Photographs showing the pattern of AgNOR staining in 
DCIS with cribriform pattern. Path. No. 505/05 
Fig 27 Photograph showing pattern of AgNOR staining in infiltrating ductal 
carcinoma. Path No. 1016/05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15 Fibroadenoma – smear showing antler-like papillary fronds. 
(H&E, x100) Cyt No. 33/05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16 Fibroadenoma – smear shows large honeycombed sheets of  
tightly packed uniform ductal cells. (H&E, x400) Cyt No. 83/05 
Fig 19 Mucinous carcinoma – smear shows abundant pools of mucin with 
aggregates and groups of uniform tumor cells. (H&E, x100) Cyt No. 801/05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 20 Ductal carcinoma – cellular smear showing loosely cohesive  
and individually scattered malignant cells. (H&E, x400) Cyt No. 11/05 
Fig 23 Infiltrating lobular carcinoma – section shows breast tissue  
infiltrated by small, uniform tumor cells arranged singly, in Indian file in a 
concentric fashion around the lobules. Trucut biopsy – (H&E, x100)  
Path. No.1215/05
Fig 24 Infiltrating ductal carcinoma – section shows breast tissue infiltrated by 
tumor cells in well defined nests, and cords showing glandular differentiation. 
Trucut Biopsy – (H&E, x100) Path. No. 294/04 
 
 
TABLE 1 
PETERSE’S CRITERIA OF BENIGN AND MALIGNANT  
BREAST CYTOLOGY 
 
BENIGN MALIGNANT 
Large Monolayer of cells  Cell dissociation; Arrangement in small 
clusters 
Nuclei Smaller than 16 µ Nuclei Larger than 16 µ 
Uniform nuclear size  Anisonucleosis; Irregular nuclear borders 
Absence of nucleoli Presence of Nucleoli 
Absence of necrosis  Presence of necrosis 
 
 
 
 
 
 
 
 
 
 
  
TABLE 2 
EVALUATION OF ACCURACY OF THE DIAGNOSTIC PROCEDURE 
 
Diagnosis 
Screening Test results 
Diseased Not diseased 
Total 
Positive  a (TP) b (FP) a+b 
Negative  c (FN) d (TN) c+d 
Total  a+c b+d a+b+c+d 
 
TP – True positive    FP – False positive  
FN – False negative    TN – True negative 
 
 
Formula  
     a 
 Sensitivity =   × 100  
   a+c   
 
  
   d 
Specificity =   × 100  
  b+d 
 
 
       a+d 
 Accuracy =   x 100 
     a+b+c+d 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3 
SEX INCIDENCE OF BREAST TUMOURS 
 
Females Males Tumour 
Type No. of Cases Incidence % No. of Cases Incidence % 
Benign 407 100% 00 0.0 
Malignant  409 99.6% 3 0.4% 
 
 
 
TABLE 4 
INCIDENCE OF VARIOUS BENIGN BREAST TUMOUR AND  
TUMOR LIKE LESION 
 
S. No. LESION No of cases Incidence % 
1 Fibroadenoma  246 30.14 
2 Fibrocystic disease  27 3.3 
3 Fibroadenosis  121 14.8 
4 Benign cystosarcoma phyllodes  13 1.5 
 
 
 
 
 
TABLE 5 
DECENNIAL INCIDENCE OF MALIGNANT TUMORS COMPARED 
TO TOTAL MALIGNANCIES IN THIS INSTITUTION 
 
Decade 
Total 
Malignancies 
No. of Malignant 
Breast Tumors 
Incidence % 
1960-1969 11137 664 5.9 
1970-1979 14977 715 4.8 
1980-1989 15625 710 4.5 
1990-1999 14430 866 6.0 
 
 
TABLE 6 
INCIDENCE OF SIGNS / SYMPTOMS IN BREAST TUMORS 
Benign Malignant 
Sign / Symptom 
Total Incidence % Total Incidence % 
Breast Mass 398 97.7 246 90.8 
Pain 6 1.5 18 4.4 
Nipple Discharge  3 0.76 12 2.9 
Nipple Retraction Puckering 
/ Ulceration of skin  
0 0 9 2.2 
 
 
 
 
TABLE 7 
PERCENTAGE OF BREAST CANCER CASES IN EACH STAGE  
 
Current Study 
Stage 
No. % 
I 47 17.3 
II 70 25.8 
III A 62 22.9 
III B 15 5.5 
IV 5 1.8 
Unstaged 73 26.6 
Total Cases 272*  
 
 NOTE: * - Represents those cases with FNAC and trucut biopsy.   
  
 
TABLE 8 
INCIDENCE OF HISTOLOGICAL TYPES OF MALIGNANT  
BREAST TUMOURS 
 
Current Study 
S. No Histological Type 
Total Cases % 
1 Ductal Carcinoma in Situ  2 0.5 
2 Invasive ductal carcinoma (NOS)  389 95.1 
3 Invasive lobular carcinoma  4 0.9 
4 Invasive ductal carcinoma with 
predominant intraductal 
carcinoma  
1 0.24 
5 Medullary carcinoma  1 0.24 
6 Mucinous / Colloid carcinoma  10 2.4 
7 Paget’s disease of nipple  2 0.48 
 
 
 
 
 
ABLE 9 
 
Diagnosis No. of Cases 
Normal Control 1 
Fibroadenoma 12 
Fibrocystic disease 4 
Fibrocystic disease with DCIS 1 
Infiltrating ductal carcinoma 15 
Infiltrating lobular carcinoma 2 
Total 35 
 
 
 
 
 
 
TABLE 10 
Mean AGNOR Value  
counting  method 
 No. of. 
Cases Type I Type II 
Normal control  1 1.2/±.2 1.2/±.2 
Fibroadenoma  12 1.5/±1.2 3.0/±1.1 
  1.0/±.6 2.5/±.3 
  1.5/±.3 2.0/±1.1 
  1.8/±.3 2.3/±1.5 
  1.3/±1.1 2.1/±1.5 
  1.2/±.5 2.6/±.3 
  1.7/±.3 2.3/±1.4 
  1.9/±.25 2.8/±.5 
  1.4/±.7 2.3/±1.1 
  1.6/±.3 2.4/±.7 
  1.1/±.4 2.7/±.5 
  1.4±.6 2.3/±.6 
Fibrocystic disease  4 2.1/±.2 3.1/±1.2 
  2.3/±1.2 2.9/±.3 
  2.1/±.4 2.7/±1.3 
   2.3/±.3 3.2/±.2 
Fibrocystic  disease 
with DC/S  
1 2.5/±2.1 3.1/±2.5 
Infiltrating ductal 
Carcinoma  
15 5.2/±1.3 9.1/±1.1 
  5.3/±1.1 9.2/±.2 
  5.2/±.25 9.4/±1.3 
  5.1/±1.2 8.3/±.5 
  4.5/±1.5 8.6/±1.5 
  4.9/±.5 9.1/±.5 
  5.3/±..2 8.7/±1.5 
  5.3/±.6 9.1/±.2 
  4.8/±1.3 8.9/±1.3 
  5.4/±1.7 9.2/±.2 
  5.1/±1.6 9.3/±.5 
  4.9/±1.2 9.6/±1.2 
  5.3/±1.5 8.9/±.3 
  5.3/±1.7 9.1/±.6 
  5.4/±1.2 9.2/±1.2 
  6.5/±1.2 8.2/±2.1 
  5.7/±.3 8.7/±.2 
 
 
 
 
 
 
 
 
TABLE 11 
PERCENTAGE OF BREAST CANCER CASES IN EACH STAGE A 
COMPARATIVE STUDY 
 
Current Study BCDDP (USA) SEER (USA) 
Stage 
No. % No. % No. % 
I 47 17.3 30 30 12 12 
II 70 25.8 37 37 57 57 
III A 62 22.9 3 3 10 10 
III B 15 5.5 0 0 3 3 
IV 5 1.8 NA NA 7 7 
Unstaged 73 26.6 30 30 11 11 
Total Cases 272  100  100  
 
 
 
 
 
 
 
 
  
TABLE 12 
COMPARATIVE STUDY OF INCIDENCE OF HISTOLOGICAL TYPES OF 
MALIGNANT BREAST TUMOURS 
 
Current Study 
S. 
No 
Histological Type Total 
Cases 
% 
Fisher et al 
% 
Usha et al 
% 
1 Ductal Carcinoma in Situ  2 0.5 5 1.9 
2 Invasive ductal carcinoma 
(NOS)  
389 95.1 67.5 77.8 
3 Invasive lobular carcinoma  4 0.9 4.9 1.9 
4 Invasive ductal carcinoma with 
predominant intraductal 
carcinoma  
1 0.24 - - 
5 Medullary carcinoma  1 0.24 6.2 10.89 
6 Mucinous / Colloid carcinoma  10 2.4 2.4 0.62 
7 Paget’s disease of nipple  2 0.48 2.3 1.9 
 
 
 
 
  
 
 
 
TABLE 13 
INCIDENCE OF BENIGN AND MALIGNANT LESION IN FNAC AND 
TRUCUT SPECIMENS ANALYSED 
 
 FNAC TRUCUT 
No. of Cases analysed 607 502 
No. of Cases (+) Benign 260 221 
No. of Cases (+) Malignant 272 256 
No. of Cases False Positive 1 1 
No. of Cases False Negative 1 11 
No. of Cases (-) for Malignancy 73 13 
Sensitivity (%) 99.6 95.2 
Specificity (%) 98.6 99.6 
Accuracy (%) 99.4 95.1 
 
 
 
  
 
 
 
 
DIAGRAM 1 
YEAR WISE DISTRIBUTION OF BREAST TUMORS 
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DIAGRAM 2 
AGE INCIDENCE OF BREAST TUMOURS 
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AgNOR score for malignant neoplasm  
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